Purpose: To determine if quantitative MRI techniques can be helpful to evaluate chronic pancreatitis (CP) in a setting of multi-institutional study. Methods: This study included a subgroup of participants (n = 101) enrolled in the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) study (NCT03099850) from February 2019 to May 2021. MRI was performed on 1.5 T using Siemens and GE scanners at seven clinical centers across the USA. Quantitative MRI parameters of the pancreas included T1 relaxation time, extracellular volume (ECV) fraction, apparent diffusion coefficient (ADC), and fat signal fraction. We report the diagnostic performance and mean values within the control (n = 50) and CP (n = 51) groups. The T1, ECV and fat signal fraction were combined to generate the quantitative MRI score (Q-MRI). Results: There was significantly higher T1 relaxation time; mean 669 ms (± 171) vs. 593 ms (± 82) (p = 0.006), ECV fraction; 40.2% (± 14.7) vs. 30.3% (± 11.9) (p < 0.001), and pancreatic fat signal fraction; 12.2% (± 5.5) vs. 8.2% (± 4.4) (p < 0.001) in the CP group compared to controls. The ADC was similar between groups (p = 0.45). The AUCs for the T1, ECV, and pancreatic fat signal fraction were 0.62, 0.72, and 0.73, respectively. The composite Q-MRI score improved the diagnostic performance (cross-validated AUC: 0.76). Conclusion: Quantitative MR parameters evaluating the pancreatic parenchyma (T1, ECV fraction, and fat signal fraction) are helpful in the diagnosis of CP. A Q-MRI score that combines these three MR parameters improves diagnostic performance. Further studies are warranted with larger study populations including patients with acute and recurrent acute pancreatitis and longitudinal follow-ups. Graphical abstract: [Figure not available: see fulltext.]
Bibliographical noteFunding Information:
Research reported in this publication was supported by National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award numbers related to: the MINIMAP study (R01DK116963) and The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) under award numbers: U01DK108328 (CDMC), U01DK108323 (IU), U01DK108306 (UPMC), U01DK108327 (OSU), U01DK108327 (CSMC), DKP3041301 (UCLA), U01DK108300 (Stanford) and U01DK108288 (Mayo). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
We acknowledge Ely Felker, MD, Shreyas Vasanawala, MD and April Fase, RN for their participation in this study. We acknowledge support of ChiRhoClin Inc. (Burtonsville, MD, USA) for supplying the Secretin (ChiRhoStim).
We present the results of a multi-institutional pilot study, Magnetic Resonance Imaging as a Non-Invasive Method for the Assessment of Pancreatic Fibrosis (MINIMAP) , funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as an ancillary study within the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) [, ]. Our aim with the MINIMAP study was to explore the potential of quantitative parenchymal MRI features serving as a non-invasive imaging biomarker for CP .
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
- Chronic pancreatitis
- Extracellular volume fraction
- Fat signal fraction
- T1 mapping
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging